Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial - The Lancet
Aurinia Demonstrates Voclosporin's Superiority over Standard-of-Care in Lupus Nephritis
Lupus nephritis: high death rate for voclosporin in Phase III
Aurinia And Voclosporin In Lupus Nephritis: The Countdown Begins (NASDAQ:AUPH) | Seeking Alpha
LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis, US
A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis - Kidney International
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial - The Lancet
Aurinia Demonstrates Voclosporin's Superiority over Standard-of-Care in Lupus Nephritis
FDA Approves Aurinia Pharmaceuticals' LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis | Business Wire
AURORA 2: Voclosporin sustains proteinuria reduction in lupus nephritis at 2 years
Safety data from clinical trials of voclosporin for plaque psoriasis | Download Table
LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis, US
Speed of Remission with the Use of Voclosporin, MMF and Low Dose Steroids: Results of a Global Lupus Nephritis Study - ACR Meeting Abstracts
VisualAbstract: Voclosporin shows clinical promise for treatment of active lupus nephritis | 2 Minute Medicine
Aurinia Demonstrates Voclosporin's Superiority over Standard-of-Care in Lupus Nephritis
Aurinia Pharmaceuticals: Comparative Analysis Reveals Voclosporin As A Drug With Mediocre Efficacy And Class-Typical Safety (NASDAQ:AUPH) | Seeking Alpha
Voclosporin for Lupus Nephritis — NephJC
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial - The Lancet
Don't Count Voclosporin Ophthalmic Solution Out (NASDAQ:AUPH) | Seeking Alpha
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial - The Lancet
Voclosporin for Lupus Nephritis: Interim Analysis of the AURORA 2 Extension Study - ACR Meeting Abstracts
Voclosporin: Hope on the Horizon for Lupus Nephritis? in: Kidney News Volume 13 Issue 2 (2021)
